Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_1
2
67%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (33.3%)
Phase 12 (66.7%)

Trials by Status

completed267%
active_not_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruitingphase_1

Study to Assess SLN124 in Patients With Polycythemia Vera

NCT05499013
completedphase_1

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

NCT04718844
completedearly_phase_1

A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

NCT04559971

Clinical Trials (3)

Showing 3 of 3 trials
NCT05499013Phase 1

Study to Assess SLN124 in Patients With Polycythemia Vera

Active Not Recruiting
NCT04718844Phase 1

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Completed
NCT04559971Early Phase 1

A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3